132 related articles for article (PubMed ID: 22964716)
21. Effect of ursodeoxycholic acid administration after liver transplantation on serum liver tests and biliary complications: a randomized clinical trial.
Wang SY; Tang HM; Chen GQ; Xu JM; Zhong L; Wang ZW; Deng GL; Xing TH; Lu LG; Peng ZH
Digestion; 2012; 86(3):208-17. PubMed ID: 22948036
[TBL] [Abstract][Full Text] [Related]
22. A combination of chenodeoxycholic acid and ursodeoxycholic acid is more effective than either alone in reducing biliary cholesterol saturation.
Podda M; Zuin M; Dioguardi ML; Festorazzi S; Dioguardi N
Hepatology; 1982; 2(3):334-9. PubMed ID: 7076116
[TBL] [Abstract][Full Text] [Related]
23. Complementary stimulation of hepatobiliary transport and detoxification by rifampicin and ursodeoxycholic acid in humans.
Duttala S; Tobi M; Dingell JD
Gastroenterology; 2006 Feb; 130(2):619-20; author reply 620. PubMed ID: 16472623
[No Abstract] [Full Text] [Related]
24. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.
Mueller M; Thorell A; Claudel T; Jha P; Koefeler H; Lackner C; Hoesel B; Fauler G; Stojakovic T; Einarsson C; Marschall HU; Trauner M
J Hepatol; 2015 Jun; 62(6):1398-404. PubMed ID: 25617503
[TBL] [Abstract][Full Text] [Related]
25. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
Razori MV; Maidagan PM; Ciriaci N; Andermatten RB; Barosso IR; Martín PL; Basiglio CL; Sánchez Pozzi EJ; Ruiz ML; Roma MG
Biochem Pharmacol; 2019 Oct; 168():48-56. PubMed ID: 31202734
[TBL] [Abstract][Full Text] [Related]
26. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man.
Rust C; Sauter GH; Oswald M; Büttner J; Kullak-Ublick GA; Paumgartner G; Beuers U
Eur J Clin Invest; 2000 Feb; 30(2):135-9. PubMed ID: 10651838
[TBL] [Abstract][Full Text] [Related]
27. A nontumorigenic variant of FGF19 treats cholestatic liver diseases.
Luo J; Ko B; Elliott M; Zhou M; Lindhout DA; Phung V; To C; Learned RM; Tian H; DePaoli AM; Ling L
Sci Transl Med; 2014 Jul; 6(247):247ra100. PubMed ID: 25080475
[TBL] [Abstract][Full Text] [Related]
28. Effect of oral ursodeoxycholic acid on bile acids tolerance tests in healthy dogs.
Abraham LA; Charles JA; Holloway SA
Aust Vet J; 2004 Mar; 82(3):157-60. PubMed ID: 15088982
[TBL] [Abstract][Full Text] [Related]
29. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
[TBL] [Abstract][Full Text] [Related]
30. Ursodeoxycholate modulates bile flow and bile salt pool independently from the cystic fibrosis transmembrane regulator (Cftr) in mice.
Bodewes FA; Wouthuyzen-Bakker M; Bijvelds MJ; Havinga R; de Jonge HR; Verkade HJ
Am J Physiol Gastrointest Liver Physiol; 2012 May; 302(9):G1035-42. PubMed ID: 22301109
[TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacokinetics of therapeutic bile acids.
Crosignani A; Setchell KD; Invernizzi P; Larghi A; Rodrigues CM; Podda M
Clin Pharmacokinet; 1996 May; 30(5):333-58. PubMed ID: 8743334
[TBL] [Abstract][Full Text] [Related]
32. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study.
Eriksson LS; Olsson R; Glauman H; Prytz H; Befrits R; Rydén BO; Einarsson K; Lindgren S; Wallerstedt S; Wedén M
Scand J Gastroenterol; 1997 Feb; 32(2):179-86. PubMed ID: 9051880
[TBL] [Abstract][Full Text] [Related]
33. Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels.
Angelin B; Ewerth S; Einarsson K
J Lipid Res; 1983 Apr; 24(4):461-8. PubMed ID: 6854153
[TBL] [Abstract][Full Text] [Related]
34. Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man.
Beuers U; Fischer S; Spengler U; Paumgartner G
J Hepatol; 1991 Jul; 13(1):97-103. PubMed ID: 1918882
[TBL] [Abstract][Full Text] [Related]
35. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.
Combes B; Emerson SS; Flye NL; Munoz SJ; Luketic VA; Mayo MJ; McCashland TM; Zetterman RK; Peters MG; Di Bisceglie AM; Benner KG; Kowdley KV; Carithers RL; Rosoff L; Garcia-Tsao G; Boyer JL; Boyer TD; Martinez EJ; Bass NM; Lake JR; Barnes DS; Bonacini M; Lindsay KL; Mills AS; Markin RS; Rubin R; West AB; Wheeler DE; Contos MJ; Hofmann AF
Hepatology; 2005 Nov; 42(5):1184-93. PubMed ID: 16250039
[TBL] [Abstract][Full Text] [Related]
36. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy.
Geenes V; Chambers J; Khurana R; Shemer EW; Sia W; Mandair D; Elias E; Marschall HU; Hague W; Williamson C
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():59-63. PubMed ID: 25864112
[TBL] [Abstract][Full Text] [Related]
37. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
38. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Pojer C; Zenz R; Lammert F; Stieger B; Meier PJ; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2001 Jul; 121(1):170-83. PubMed ID: 11438506
[TBL] [Abstract][Full Text] [Related]
39. Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.
Wang R; Liu L; Sheps JA; Forrest D; Hofmann AF; Hagey LR; Ling V
Am J Physiol Gastrointest Liver Physiol; 2013 Aug; 305(4):G286-94. PubMed ID: 23764895
[TBL] [Abstract][Full Text] [Related]
40. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
